Endo lifts stay of FDA litigation following launch of bulk-compounded Vasopressin product
Endo announced it is lifting a temporary stay of its litigation against the FDA. The litigation, filed in the U.S. District Court for the District of Columbia, seeks a declaration that FDA's "Interim Policy" on compounding using bulk drug substances under Section 503B of the DQSA. August 15, 2018